Hyperreflective foci, OCT progression indicators in age-related macular

degeneration, include transdifferentiated retinal pigment epithelium

Dongfeng Cao PhD[1‡], Belinda Leong MD[2,4‡], Jeffrey D. Messinger DC [1], Deepayan

Kar MS [1], Thomas Ach MD[5], Lawrence A. Yannuzzi MD [2,3], K. Bailey Freund MD[2,3,6],

Christine A. Curcio PhD[1]*

[1]Department of Ophthalmology and Visual Sciences, University of Alabama at

Birmingham School of Medicine; Birmingham, AL, USA.

[2]Vitreous Retina Macula Consultants of New York; New York, NY, USA.

[3]LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital;

New York, NY, USA.

[4]Retina Associates; Sydney, NSW, Australia.

[5]Department of Ophthalmology, University Hospital Bonn; Bonn, Germany.

[6]Department of Ophthalmology, New York University, Grossman School of Medicine;

New York, NY, USA.

*Corresponding author. Email: christinecurcio@uabmc.edu

‡These authors contributed equally to this work.

Short title: RPE transdifferentiation in AMD

Words: 4676 (main), **Figures:** 9; **Supplementary figures:** 7; **Supplementary tables:** 7

Previous meeting presentations: annual meeting of the Association for Research in

Vision and Ophthalmology, 2019 (clinical imaging) and 2020 (laboratory study)

ABSTRACT

Purpose: By optical coherence tomography (OCT) imaging, hyperreflective foci (HRF) indicate progression risk for advanced age-related macular degeneration (AMD) and are in part attributable to ectopic retinal pigment epithelium (RPE). We hypothesized that ectopic RPE are molecularly distinct from in-layer cells and that their cross-retinal course follows Müller glia.

Method: In clinical OCT (61 eyes, 44 AMD patients, 79.4 ± 7.7 years; 29 female; follow-up = 4.7 ± 0.9 years) one HRF type, RPE plume, was reviewed. Twenty eyes of 20 donors characterized by *ex vivo* OCT were analyzed by histology (normal, 4; early/intermediate AMD, 7; geographic atrophy (GA), 6; 3 neovascular AMD (nvAMD). Cryosections were stained with antibodies to retinoid (RPE65, CRALPB) and immune (CD68, CD163) markers. In published RPE cellular phenotypes, red immunoreactivity was assessed semi-quantitatively by one observer (none, some cells, all cells).

Results: Trajectories of RPE plume and cellular debris paralleled Müller glia, whether ordered or subsident, near atrophy borders. RPE corresponding to HRF lost immunoreactivity for retinoid markers and gained immunoreactivity for immune markers. Aberrant immunoreactivity appeared in individual in-layer RPE cells and extended to all abnormal phenotypes. Müller glia remained CRALBP-positive. Plume cells approached and contacted retinal capillaries.

Conclusion: Gain- and loss-of-function starts with individual in-layer RPE cells and extends to all abnormal phenotypes. Down-regulated RPE retinoid handling may impair rod vision while Müller glia sustain cone vision. Evidence for RPE transdifferentiation, possibly due to ischemia, supports a proposed process of epithelial-mesenchyme transition. Data can propel new biomarkers and therapeutic strategies for AMD.

Key words: age-related macular degeneration, hyperreflective foci, retinal pigment

epithelium, optical coherence tomography, immunohistochemistry, retinoids, immune

markers, epithelial-mesenchyme transition

Abbreviations: AMD, Age-related macular degeneration; OCT, optical coherence

tomography; HRF, hyperreflective foci; BLamD, basal laminar deposit; BrM, Bruch's

membrane; Ch, choroid; ChC, choriocapillaris; cRORA, complete RPE and outer retinal

atrophy; d, drusen; ELM, external limiting membrane; EZ, ellipsoid zone; fv scar,

fibrovascular scar; GCL, Ganglion cell layer; HFL, Henle fiber layer; ILM, internal limiting

membrane; IPL, inner plexiform layer; INL, inner nuclear layer; IS, inner segments of

photoreceptors; iRORA, complete RPE and outer retinal atrophy; IZ, interdigitation zone;

nvAMD, neovascular AMD; ONL, outer nuclear layer; OPL, outer plexiform layer; OS,

outer segments of photoreceptors; R, retina; RPE, retinal pigment epithelium; Sc, sclera;

SRS, subretinal space; x, detachment.

Précis: Hyperreflective foci (HRF) are OCT progression risk indicators in age-related

macular degeneration. Abnormal RPE cells including some that correspond to HRF lose

immunoreactivity for retinoid markers and gain immunoreactivity for immune markers,

indicating molecular transdifferentiation.

INTRODUCTION

Age-related macular degeneration (AMD) causes vision loss in older persons worldwide.

[1] Neovascular complications are managed medically, [2] whereas the underlying and

prevalent atrophic ("dry") disease is not yet treatable. AMD affects vertically integrated

cellular layers formed by light-sensing photoreceptors and support cells (retinal pigment

epithelium (RPE), choriocapillaris, Müller glia). Characteristic extracellular deposits

(drusen, subretinal drusenoid deposits) form between photoreceptors and their choroidal

and retinal blood supplies. [3]

AMD is increasingly understood via clinical optical coherence tomography (OCT).

This technology provides depth-resolved and registered images of retinal and choroidal

tissue layers [4] that resemble histology and can be followed over time. [5] Not only are RPE

cells central to, and impacted by, both atrophic and neovascular AMD, they can be

uniquely monitored in vivo by OCT. RPE health is also an OCT readout of the less

visible Bruch's membrane and choriocapillaris. Each RPE cell has >1400 organelles [6]

capable of generating OCT reflectivity. Further, as neovascular AMD is managed

clinically, many OCT images of at-risk eyes are captured. A progression sequence for

drusen-initiated atrophy supported by OCT and histology is age-related deterioration of

choriocapillaris and Bruch's membrane preventing egress of wastes to the circulation,

growth of drusen with death or migration of overlying RPE, and reactive gliosis. [5]

Longitudinal studies and post-hoc analysis of clinical trial imaging datasets

revealed OCT biomarkers for progression from intermediate AMD to geographic atrophy.

Tissue damage in atrophy is severe and possibly irreversible. [7] Currently the only

imaging outcome accepted by the U.S. Food and Drug Administration for AMD trials is

slowing the expansion of atrophy. Identifying outcome measures earlier in disease

progression is the goal of an international consensus group. [5, 8-10] Of OCT biomarkers,

hyperreflective foci (HRF) within the neurosensory retina confer the largest progression

risk. [11-14]Our histologic survey of RPE phenotypes in AMD, [15-17] confirmed in clinically

characterized eyes, [15, 18] identified two RPE phenotypes corresponding to HRF. These

are "sloughed" cells in the subretinal space and "intraretinal" cells within the

neurosensory retina. In a hypothetical progression sequence (Fig. 1), morphologically

distinct cells deploy along separate pathways of cell fate. These include death,

migration, and transdifferentiation to other cell types, without intervening dedifferentiation

and proliferation. [19] Due to migration and death-in-place of RPE, the layer disintegrates,

scattering fully pigmented and nucleated cells ("dissociated") across atrophic areas.

Some cells appear to dive below the intact layer and migrate outside the atrophic area

("subducted"). [16] In neovascular AMD, lipid filled non-RPE cells also correlated to HRF [18,

20] and may represent microglia, macrophages, or both.

We postulated that one HRF form called "RPE plume" represents cells crossing the

retina within the Henle fiber layer (HFL), which varies in thickness and angle with retinal

position (Supplementary Fig. 1). [17] We herein provide a clinical OCT description for this

feature in patients with AMD and show RPE-derived debris in relation to the cross-retinal

course of Müller glia. To probe the identity of HRF and test whether they include

transdifferentiated RPE, we used immunohistochemistry of human donor eyes to show

loss of retinoid processing and gain of immunologic function in all abnormal RPE

phenotypes. Widespread RPE transdifferentiation, consistent with a proposed process of

epithelial-mesenchyme transition, [21] supports a strategy of visualizing and targeting

pathology earlier in AMD progression than atrophy.

MATERIALS AND METHODS

Compliance

Study of a clinical cohort and use of human tissue samples was approved by institutional

review at Vitreous Macula Retina and University of Alabama at Birmingham (IRB-

150910011), respectively, and complied with the Health Insurance Portability and

Accountability Act of 1996 and the Declaration of Helsinki.

Patient selection, clinical image capture, and image analysis

Consensus nomenclature was used for reflective bands of OCT. [22] RPE+BL band refers

to the RPE and its basal lamina atop drusen or other material in the sub-RPE-BL space.

This space is between RPE-BL and inner collagenous layer of Bruch's membrane. [23]

To analyze RPE plume natural history, patients with non-neovascular AMD on

OCT imaging seen by specialists (authors KBF, LAY) at a tertiary private retinal practice

were retrospectively reviewed (author BL). Inclusion criteria included age >50 years, >12

months of follow-up with tracked OCT B-scans at an inter-scan spacing of ≤250 µm, and

maximum follow-up interval of 6 months, and at least one eye containing HRF. HRF

were defined as features with reflectivity like that of the RPE, separated from the RPE

layer (i.e., discrete HRF), and thought to originate from the RPE layer. Reduced

RPE+BL thickness in a scan subsequent to HRF appearance was considered evidence

for RPE origin. Patients with diabetic retinopathy, retinal vascular disease, previous

vitreoretinal surgery, laser treatment or ocular inflammation were excluded. Eyes were

evaluated at baseline by presence of AMD lesions including soft and cuticular drusen,

subretinal drusenoid deposits, and acquired vitelliform lesions [24]). If color fundus

photographs were available, pigmentary changes were also considered. Presence of

drusenoid pigment epithelial detachment [25] and complete RPE and outer retinal atrophy

(cRORA) [9] was noted.

All patients underwent spectral domain OCT and near-infrared reflectance imaging

(Spectralis HRA + OCT, Heidelberg Engineering, Heidelberg, Germany) with eye

tracking enabled. The OCT protocol comprised 20° horizontal raster line scans centered

on the fovea (19 to 49 B-scans per eye; scan spacing at 115 to 250 µm, automatic real-

time averaging between 4 and 23).

Consecutive tracked OCT and near-infrared reflectance images were analyzed

over time and with reference to the foveal center, from the date of HRF appearance.

Plume status over time was recorded as no change, change to a different morphology,

formation of a discrete HRF as defined above, and dissolution. Plume direction towards

the OPL was noted as congruent or incongruent with normal HFL architecture

(Supplementary Fig. 1), i.e., parallel or non-parallel with fibers. To evaluate plumes as

progression indicators, expansion of cRORA and drusen growth and collapse were also

noted.

Overview of laboratory studies

To elucidate the molecular repertoire of RPE phenotypes corresponding to HRF,

we obtained human donor eyes with and without AMD and performed

immunohistochemistry. We used antibodies for retinoid- and immune-related proteins [26]

(Supplementary Table 1) and positive and negative controls in human tissues

(Supplementary Fig. 2). Cryosections were processed with an avidin-biotin-peroxidase

immunohistochemistry detection system and a red reaction product. We checked the

immunolabeling of all RPE phenotypes [27] (Supplementary Table 2) using bright field

microscopy for direct observation of cellular pigmentation and status of surrounding

tissue.

Donor eye acquisition, *ex vivo* imaging, AMD diagnosis

Whole eyes were obtained from deceased human donors (≥ 80 years of age,

white, non-diabetic, and ≤6 hours death-to-preservation) to the Advancing Sight Network

(Birmingham AL USA) during 2016-17. Eye health history was not available. After

anterior segment removal, eyes were preserved in 4% buffered paraformaldehyde,

screened for AMD using *ex vivo* multimodal imaging including OCT [17] (details in

Results). Tissues were stored in 1% buffered paraformaldehyde at 4°C until used.

Rectangles of full-thickness eye wall (5x8 mm) including fovea and optic nerve

were dissected. To prevent ice crystals, tissue was cryoprotected in ascending

concentrations of sucrose in phosphate buffered saline (PBS) then ascending

concentrations of tissue embedding medium and sucrose buffer (HistoPrep, Thermo

Fisher Scientific, #SH75-1250D, Rockford IL USA); 4 parts sucrose buffer and 1 part

medium then 2:1 sucrose: medium. Tissue was placed into a cryomold (Electron

Microscopy Sciences, #70176-10, Fort Washington PA USA) with embedding medium,

oriented, frozen in liquid nitrogen, and stored at -80°C. Tissues were sectioned at 12 μm

thickness on a cryostat (Leica CM3050 Vashaw Scientific, Norcross GA USA), air dried

at 37°C overnight, and stored at -80°C until used.

For AMD diagnosis and imaging-histology correlation, cryosections through the

fovea and perifovea (recognized by HFL) were stained with periodic acid Schiff

hematoxylin to highlight Bruch's membrane and sub-RPE deposits. One stained section

per slide was scanned with a 20X objective and a robotic microscope stage (Olympus

VSI 120, CellSens; Olympus, Center Valley PA), scaled to tissue units, and centered on

the fovea or vertical meridian (where Henle fibers diverge) using a custom plugin for FIJI

(https://imagej.nih.gov/ij/download.html). *Ex vivo* OCT B-scans and scanned whole

sections were matched for major landmarks (e.g., overall tissue contour, foveal center,

large vessels, individual pathologies). For detailed examination, some sections were

scanned with a 60X oil immersion objective (numerical aperture = 1.4). For figures,

images were adjusted to maximize the intensity histogram for contrast and white balance

and made into composites (Photoshop CS6, Adobe Systems, USA).

Immunohistochemistry and evaluation

Detailed methods for immunohistochemistry are available in the Supplementary

Materials.

Glass slides were scanned using the system described above and 20x and 40x

objectives. RPE phenotype was categorized using the Project MACULA grading system.

[15, 16] (Supplementary Table 2). In each stained section (1 per antibody per eye),

immunoreactivities for each RPE phenotype were scored semi-quantitatively by a single

observer (author DC after training by author CAC) as 0-not stained, 1-some stained and

2- all stained. These scores were converted to percentages using by total scores of eyes

for each phenotype divided by maximum score (2 x number of eyes with the phenotype)

times 100. Each phenotype was seen in at least 3 eyes.

RESULTS

Clinical imaging

Four morphologies of RPE plume were defined (Fig 2). Curvilinear plumes (Fig. 2A)

appear as hyperreflective features of constant width, above the RPE layer with or

without drusen, and pointing towards the outer plexiform layer. Relative to curvilinear,

comma plumes (Fig. 2B) are similarly reflective, with a wider base at the RPE layer and

tapering anteriorly. Like curvilinear, thread plumes (Fig. 2C), previously seen in inherited

retinopathies, [28] are of uniform width but are thinner. A vitelliform plume (Fig. 2D) is thick

at its base, typically an acquired vitelliform lesion (autofluorescent and yellow subretinal

extracellular material), [24] with an anterior taper that widens over time.

To observe plume lifecycles and intraretinal trajectories, 44 patients with non-

neovascular AMD (61 eyes, 29 females, 79.4 years (standard deviation 7.7 years)) with

at least one HRF were enrolled (Supplementary Table 3). In 29 eyes of 21 patients (15

female), 129 plumes were localized and followed for characteristics including presence

of cRORA and iRORA). [5, 9] Mean follow-up duration was 4.67 years (standard deviation

0.09 years). As shown in Supplementary Fig. 3A-B, plumes obliquely crossing

horizontally oriented OCT B-scans appeared as small reflective dots that were

connected by inspecting consecutive scans. Over time individual plumes evolved

considerably (Fig. 3), converting from one morphology to another (Fig. 3B,D,E) or to

discrete HRF as defined above (Fig. 3C). They also disappeared with (Fig. 3A,B,D) or

persisted after (Fig. 3A, B, C, D) druse collapse to atrophy. One plume preceded druse

appearance (Fig. 3E).

Curvilinear and thread plumes were the most common morphologies at baseline

and the longest lasting over follow up (Supplementary Fig. 4A). Plume number and

dynamism (i.e., appearance, disappearance, and conversions) could be striking

(Supplementary Fig. 4B). Of 129 plumes at baseline (Supplementary Table 4), 73

(56.6%) converted to another plume morphology or discrete HRF during follow-up, with

38 disappearing and 35 remaining; 56 (43.4%) plumes retained the original morphology.

Most plumes (101/129, 78.3%) were geometrically congruent with the local

trajectory of the normal HFL (Supplementary Table 5), especially temporal to the fovea.

More non-congruent plumes appeared superior nasal to the fovea than in other

quadrants. Of 129 plumes, 73 (56.6%) were associated with cRORA. Near cRORA,

plumes were seen traveling in directions unrelated or opposite to the normal HFL

(Supplementary Fig. 5). Accordingly, at the final visit (Supplementary Table 6), 48 of 129

(37.2%) plumes associated with cRORA were congruent with the local normal HFL and

25 of 129 (19.4%) were incongruent, with 16/129 (12.4%) of incongruent plumes located

at the cRORA border. In contrast, all 6/129 (4.7%) plumes associated with iRORA were

congruent with the HFL. Finally, 50/129 (38.8%) of plumes were not associated with

either cRORA or iRORA.

Laboratory study

To molecularly characterize normal and abnormal RPE cells, especially those

corresponding to HRF, we used *ex vivo* OCT imaging to find human donor eyes with

AMD (Fig. 4). HRF found in macular OCT B-scans were matched with pigmented cells in

the subretinal space and retina of stained sections (Fig. 4). Atrophic AMD eyes with RPE

plume in OCT exhibited pigmented cells in the outer nuclear layer (ONL) and HFL on

histology (Fig. 4, C1 to C2 and F1 to F2). Results are based on 20 eyes of 20 donors

(mean age 89.2 ± 5.0 years; 16 total AMD (7 early-intermediate, 6 atrophic, 3

neovascular, 4 control), with mean time from death to preservation of 3.9 ± 0.7 hours

(Supplementary Table 7).

Gain of immune function

We begin by demonstrating that cells of RPE origin label with antibodies against

two well-known immune cell markers, Cluster of Differentiation (CD)68 and CD163. [29]

CD68 is a transmembrane glycoprotein that is abundantly expressed by macrophages

and widely used as a myeloid-specific marker. [30] CD68 is one member (LAMP-4) of a 5-

protein family that together accounts for 50% of the protein in lysosome membranes. [30]

In tissue sections (Fig. 5), positive controls for CD68 immunoreactivity are choroidal

macrophages (Fig. 5D) and negative controls are healthy RPE (Fig. 5A). Fully

pigmented cells in the neurosensory retina are strongly CD68+ (Fig. 5F). Importantly,

individual sloughed cells in the subretinal space (Fig. 5C and 5F) are also positive, as

are individual cells still within the layer (Fig. 5E). Dissociated RPE scattered in the

atrophic area are universally labeled (Fig 5H and 5N), as are cells under the continuous

layer (Fig. 5I), and within tubes of scrolled photoreceptors (Fig. 5J and 5K; outer retinal

tubulation[31]). Some bilaminar (Fig. 5D) and melanotic (Fig. 5M) cells are CD68+.

CD163 is a high-affinity haptoglobin-hemoglobin scavenger found in bone marrow-

derived macrophages [32] and in retinal cells resembling microglia. [33-35] The latter are

phagocytes of embryologic yolk sac origin that reside in inner retina when quiescent and

migrate into outer retina when photoreceptors are damaged. [33] Figure 6 shows that anti-

CD163 labels inner retina cells but not the normal RPE layer, as expected. It does label

abnormal RPE phenotypes in a pattern like that of CD68, with overall lighter reaction

product. These include fully pigmented CD163+ cells in the ONL (Fig. 6Fand 6N), HFL

(Fig. 6L), above (Fig. 6E and 6I) and below (Fig. 6I) the continuous RPE layer in the

subretinal and sub-RPE-basal laminar spaces, respectively, and dissociated cells in

atrophic areas (Fig. 6 H, 6J and 6K).

Loss of retinoid function

Next, we show that abnormal RPE cells cease to exhibit detectable quantities of

retinoid processing proteins essential for vision. Rod-mediated (dim light) vision is

affected early in AMD, because rods depend on the choriocapillaris-Bruch's membrane-

RPE complex. [36] Cone-mediated (bright light) vision, which is also sustained by Müller

glia and retinal vessels, [37] persists into later disease.

We begin with RPE65, the isomerohydrolase of the classic visual cycle. RPE65

catalyzes the conversion of retinyl esters to 11-cis-retinol, which is subsequently

oxidized to 11-cis-retinal, required for visual transduction by rod and cone

photoreceptors. [38] Figure 7 shows that in AMD eyes, intraretinal RPE in ONL (Fig. 7F)

and individual sloughed cells overlying the continuous layer (Fig. 7C and 7L) lack

RPE65-immunoreactivity. Cells in areas of photoreceptor degeneration and depletion

are also RPE65-, including dissociated (Fig. 7N), subducted (Fig. 7I) and entubulated

(Fig. 7J) cells. Importantly, some individual cells in the continuous layer are RPE65- (Fig.

7F and 7H). Interestingly some bilaminar cells within fibrotic scars of neovascular AMD

remain RPE65+ (Fig. 7M).

Cellular retinal binding protein (CRALBP) is important in the RPE-based visual

cycle. It is also expressed by Müller glia in a second visual cycle thought to supply

cones. [37, 39] CRALBP is a 36-kDa water-soluble protein with 2 conformational states

facilitating intracellular transport of hydrophobic 11-cis retinoids. [40] Figure 8 shows that

healthy RPE has a strong CRALBP signal (Fig. 8A). In AMD, ectopic RPE in the ONL,

recognizable by pigment load, are CRALBP- (Fig. 8F and 8L). Individual sloughed cells

(Fig. 8H and 8L) and in-layer cells (Fig. 8E) are also negative as are pigmented cells in

atrophic areas (dissociated, Fig. 8C, 8K and 8N; subducted, Fig. 8I). Shed granule

aggregates [15, 41] are CRALBP-, under a continuous CRALBP+ layer (Fig. 8B, J).

In contrast to RPE, Müller glia remain strongly CRALBP+ in their cross-retinal

course, regardless of the degree of photoreceptor loss. Distinctive features (Fig. 8L) are

the external limiting membrane (junctional complexes between glia and photoreceptors)

[42] and pericellular baskets [43] around ONL cell bodies. In the HFL of areas with lesser

disease involvement, stained Müller glia are parallel and straight (ordered, [7] Fig. 8L). At

the border of atrophy (descent of the external limiting membrane, [44] Fig. 8C, 8K and 8N)

and outer retinal tubulation (Fig. 8J), CRALBP+ fibers curve down towards Bruch's

membrane and then head laterally, parallel to it. In some locations immunolabeled fibers

zig-zag in parallel, presenting cross-sections of dots and lines (disordered, [7] Fig. 8F and

8N). CRALBP signal also appears in fibrotic scars resulting from neovascular AMD (Fig.

8D, 8G and 8M).

Semi-quantitative assessment of immunohistochemistry

The number of stained cells in each RPE phenotype was assessed a semi-

quantitatively (0, not stained; 1, some cells of a phenotype stained; 2, all cells stained).

These scores were summed and expressed as a percent of the highest possible score,

as if all phenotypes had been stained completely by each antibody. Supplementary

Figure 6A shows that all RPE phenotypes were found in immuno-stained sections of

these 16 AMD eyes, with similar patterns in neighboring sections. Supplementary Figure

6B graphically summarizes the marker studies. Age-normal uniform and non-uniform

RPE is positive for retinoid markers and negative for immune markers. Abnormal RPE

phenotypes have overall less retinoid immunoreactivity (although some stained cells

were found at 5%) and universally more immune marker immunoreactivity (up to 75%).

Thus, cells corresponding to HRF in OCT are part of an overall pattern of

transdifferentiation resulting in gain-of-function and loss-of-function of RPE.

Histology of plume lifecycle

Our clinical study indicated that RPE plumes have lifecycles that are observable in

vivo. We previously showed in type 3 (intraretinal) neovascularization that RPE cells

contact the deep capillary plexus. [18] Figure 9, A to C accordingly shows RPE plume cells

crossing the HFL to approach and encircle capillaries of this plexus. Cells are nucleated

and contain numerous RPE-characteristic spindle-shaped melanosomes and

melanolipofuscin granules. Fine processes extend along a capillary (Fig. 9D).

We previously showed RPE organelles in the HFL of photoreceptor-depleted

atrophic areas, [7] suggesting that Müller glia ingested and cleared debris from

degenerating RPE. Here we show region-specific distribution of RPE organelles,

consistent with the local trajectory of Müller glia. In the macula, Müller glia are Z-shaped.

[45] Fibers are oriented vertically in the ONL, obliquely in the HFL, and vertically in the

OPL and inner retinal layers (Supplementary Fig. 1). In plumes near the fovea (Fig. 9E

and 9F; Fig. 6N), fully pigmented RPE cells obliquely cross the HFL, with individual and

grouped organelles in the lead. The path turns vertically at the INL and IPL, following a

Z-shaped course. In contrast, in the peripheral retina, where Müller glia are vertical,

Supplementary Figure 7 shows melanosomes on a vertical track away from RPE above

a druse.

DISCUSSION

For RPE plume, one HRF type in AMD, we established a clinical lifecycle, including both

cRORA and resolution without cRORA, with evidence of clearance by Müller glia. HRF

are one of four OCT indicators in a composite risk score for AMD progression (with soft

and calcified drusen, plus subretinal drusenoid deposit).[46] Of these four, HRF confer the

largest risk (odds ratio at 24 months, 5.21 (3.29-8.26)),[13] yet have received histologic

investigation only recently, a gap that is herein addressed. We provide strong evidence

that ectopic RPE can manifest as HRF, without excluding the possibility that other cells,

such as microglia, macrophages, or both, may also correspond to HRF, as they do in

nvAMD.[18, 20] We further show that sloughed and intraretinal cells corresponding to HRF

are two of many abnormal RPE phenotypes undergoing molecular transdifferentiation.

Our parallel findings of CD68 and CD163 immunoreactivity in all abnormal RPE

phenotypes adds important new information to a decades-old debate [47, 48] about whether

RPE, a phagocyte itself, shares or assumes properties of other phagocytes. This

investigation like our previous studies used high resolution comprehensive microscopy

to link cells with characteristic RPE organelles [15, 16] to a time course of activity visible

through longitudinal clinical imaging. Our cellular phenotyping system [15] built on prior

literature and is used by others. [49, 50] We posited that these phenotypes represented

discrete steps towards death, migration, or transdifferentiation of individual cells that

could be followed over time in OCT due to high RPE reflectivity. In prior electron

microscopic analysis of pigmented cells corresponding to HRF [51] we did not observe

phagolysosomes, i.e., cytoplasmic vacuoles formed by phagosomes with ingested

material fusing with lysosomes, as expected from phagocyte activity. In a separate study

of HRF over a large drusenoid pigment detachment, [17] all detectable HRF could be

attributed to fully pigmented and nucleated intraretinal cells. In clinical cases of that prior

study, [17] HRF appeared in the retina vertically above and several months after

disturbances of the RPE layer. Our current data further show that individual in-layer cells

and all abnormal phenotypes exhibit CD68 and CD163 immunoreactivity. We cannot

exclude the possibility that phagocytes ingest and retain characteristic RPE organelles,

seamlessly intercalate into the layer, and either become abnormal phenotypes or induce

them. However, extensive transdifferentiation in response to common perturbations is

also a parsimonious explanation.

We emphasize that snapshot immuno-detection of CD68, a lysosomal protein of

unknown function reliably found in macrophages of myeloid origin, [30] does not indicate

that labeled cells have assumed macrophage behavior. Our data do not imply that

macrophages of hematopoietic origin previously shown in choroid and sub-RPE-BL

space [52, 53] started as RPE. Our data do not bear on the identity of CD68+ cells seen by

others, e.g., high-passage cultured RPE [54] and surgically excised neovascular

membranes. [55, 56] In rapidly preserved eyes with experimental laser-injury, individual

detached cells atop an intact RPE layer are CD68+ [57](compare to Fig. 5C and Fig. 6C).

Recent authors interpreted CD68+ cells in aqueous after RPE tear [58] and in proliferative

vitreoretinopathy [59] as RPE. CD68+ cells in the outer junctional zone of atrophy in AMD

were demonstrated by laser confocal microscopy and immunofluorescence. [49] This

technique does not directly reveal melanin, and the authors did not comment on cellular

identity. [49]

Our data illuminate subducted cells on the inner collagenous layer of Bruch's

membrane containing RPE organelles and originally called "spent RPE". [60] Using single

continuous high-resolution histologic sections of eyes with cRORA, we saw plausible

transitional morphologies between fully pigmented RPE outside atrophic areas and

flattened cells with fewer organelles in the sub-RPE-BL space. [16] We hypothesized that

dissociated RPE in an atrophic area, [61] loosed from constraining junctional complexes,

dove under the intact layer and moved into the outer junctional zone to participate in

atrophy expansion (Fig. 1). [16] Herein we show CD68+ and CD163+ cells and highly

pigmented RPE65- and CRALBP- cells in the same sub-RPE-BL tissue compartment of

the same eyes. The sub-RPE-BL space can harbor macrophages of myeloid origin,

multinucleate giant cells, and fibroblasts. [62] It is possible that co-localized CCR2 and

CD18 immunoreactivity in these locations, attributed to macrophages, [63] may represent

subducted and dissociated RPE, respectively. Multi-label immunohistochemistry is

needed to confirm how many subducted cells are RPE-derived. Macrophages that co-

express CD68 and CCR7 can be assigned to a ''proinflammatory'' M1 subset, whereas

CD68+ CD163+ macrophages most likely belong to an ''anti-inflammatory'' M2 subset. [64]

Longitudinal studies with higher resolution OCT [65, 66] may make it possible to detect

subducted cells and determine if they promote or retard atrophy expansion, of value to

validating this regulatorily-approved anatomic endpoint.

Our expectation of plume congruence with HFL trajectory was largely met and of

note was non-congruence near cRORA (Supplementary Table 6). This is likely due to

subsidence (sinking) of the OPL, HFL, and ONL, a committed step toward cRORA

onset. [67] Subsidence is visible where photoreceptors focally shorten and are scrolled by

Müller glia. [7, 68] Our data on plume trajectories and CRALBP immunohistochemistry thus

add to prodigious activities of Müller glia in AMD. These include descent and curving of

the ELM (border of atrophy), reactive gliosis, adherent glial seal in areas of

photoreceptor depletion, and invasion of individual drusen. [31, 44, 69, 70] CRALBP

immunohistochemistry confirmed HFL fiber geometry as well as retinoid capacity of

Müller glia, still supported by retinal circulation late in disease. Single and grouped RPE

organelles paralleling Müller glia [7, 71] are presumably carried intracellularly. In contrast

RPE cell bodies travel between HFL fibers (Fig. 8L and Fig. 9) following a trail of

organelle detritus. Active glial disassembly and removal of fragments is suspected.

Because almost 40% of plumes were not associated with atrophy at follow-up

(Supplementary Table 6), plumes should be considered indicators not predictors.

Factors underlying variable plume outcome in our study include inclusion of patients with

established disease, short observation period, and a "come and go" behavior consistent

with cells subject to constant pro-migratory stimuli being dismantled *en route*.

Given evidence that many RPE cells are transdifferentiating, HRF may indicate risk

by revealing an overall level and type of disease activity. Epithelial-mesenchyme-

transition (EMT) is one candidate activity. In this complex process, cells lose apical-

basal polarity, modulate cytoskeleton, and reduce cell-cell adhesion. [72] A defining

feature of an epithelium is localization within organs stabilized by a basal lamina and

integrin-mediated interactions with extracellular matrix. Epithelial cells that detach from

extracellular matrix normally undergo a programmed cell death called anoikis. [73, 74]

Tumor cells of epithelioid origin can escape anoikis by EMT. Thus, they assume

amoeboid morphology, become motile and invasive, and travel in the circulation to other

organs, with most dying *en route*. EMT of RPE has been suspected in AMD due to

findings of characteristic molecular markers (vimentin [76] and the transcription factor

Snail1 [21]) and the presence of HRF. [75] Another contributor is the separation of the RPE-

BL from its native basal lamina by BLamD, [23, 77] an extracellular matrix that also contains

other components. RPE cells undergoing EMT might indeed resist cell death [21] but they

may also be dysfunctional, due to gain- and loss-of-function suggested by our data. One

factor promoting EMT over anoikis is hypoxia, [74] of high AMD relevance due to age- and

disease-related loss of choroid and choriocapillaris [78-81] and the distancing of RPE from

choriocapillaris by BLamD and drusen. [82] Thus we showed RPE cells not only contacting

the deep capillary plexus (**Fig. 9** [17, 18]) but also aiming towards and clustering around

vessels as a seemingly coordinated group (**Fig. 9**) rather than as single cells. Parallels

with cancer are appropriate due to the unusual metabolic demands of photoreceptors

and their supporting system compared to other neurons. The retina, of all body tissues,

shares with tumors a dependence on aerobic glycolysis (the Warburg effect). [83-85] A

consensus group of cancer researchers recently advocated monitoring cellular

properties as part of the main criteria for EMT, along with molecular markers. [72] The high

OCT visibility of RPE makes it uniquely possible to view these cellular activities in AMD.

Strengths of the clinical study are high-quality images and long follow-up on known

progression risk factors. Limitations include the small number of patients and lack of

independently assessed HFL trajectory with directional OCT. [86] Strengths of the

laboratory study are short post-mortem specimens with attached retinas, comprehensive

photomicroscopy to visualize pigment, a color-contrasting readout for immunoreactivity,

and a cross-sectional format conducive to OCT comparison. Limitations addressable in

future studies include lack of clinical records with pre-mortem imaging, lack of correlative

data from flat mounts to show early RPE pathology, limited assessments of RPE

adjacent to AMD deposits, and lack of double-label experiments to determine cell-by-cell

overlap among the four markers. Nevertheless, this is most detailed characterization of

RPE pathology in AMD to date in either clinical or laboratory settings. HRF are a

consensus OCT feature in AMD, [10] encouraging longitudinal studies in other clinical

centers, ideally with comprehensive *en face* OCT and fundus autofluorescence imaging

to determine the proportion of HRF that are RPE-derived. Our data can propel new

biomarker and therapeutic strategies for a common and currently untreatable cause of

impaired vision.

SUPPLEMENTARY MATERIALS

Supplementary Figures

Supplementary Figure 1. Henle fibers in the human macula.

Supplementary Figure 2. Positive and negative controls for immunohistochemistry

Supplementary Figure 3. Retinal pigment epithelium plumes exhibit directionality

Supplementary Figure 4. Duration and evolution of plumes

Supplementary Figure 5. Variations in RPE plume trajectory in atrophy.

Supplementary Figure 6. Gain- and loss-of-function of RPE and RPE-derived cells

Supplementary Figure 7. Dispersing melanosomes follow regionally specific trajectories

of Müller glia

Supplementary Tables

Supplementary Table 1. Antibodies used

Supplementary Table 2. Morphologic phenotypes of RPE and its basal lamina in AMD

Supplementary Table 3. Demographics of clinic patients and study eyes

Supplementary Table 4. Plume disposition at final visit

Supplementary Table 5. Plume trajectory relative to HFL and macular quadrant

Supplementary Table 6. Plume association with atrophy

Supplementary Table 7. Characteristics of donor eyes

Acknowledgments

We thank Advancing Sight Network (formerly the Alabama Eye Bank) for timely retrieval

of donor eyes and David Fisher for graphics in Figure 1.

Funding

This work was supported by National Institutes of Health (Bethesda, MD, USA) grant

R01EY015520 (CAC); The Macula Foundation, Inc., New York, NY; an anonymous

donor to AMD research at UAB; unrestricted funds to the Department of Ophthalmology

from Research to Prevent Blindness, Inc.; and EyeSight Foundation of Alabama.

Acquisition of human tissues for immunohistochemistry was funded by NIH grant

R01EY015520 (CAC) and R01EY027948 (CAC, TA) and IZKF Würzburg (N-304, TA).

Author contributions

C.A.C. designed, supervised study and wrote the manuscript. D.C. designed and

performed immunohistochemistry experiments. B.L. designed and conducted clinical

studies and wrote the manuscript. J.M. conducted *ex vivo* imaging, tissue cryosections,

and microscopy. D.K. made Fig. S1. T.A. edited manuscript. L.A.Y. and K.B.F designed

and supervised clinical study. K.B.F. edited manuscript. C.A.C. and T.A. raised funding.

Competing interests

T.A. receives research funding from Novartis and is a stockholder of MacRegen Inc.

K.B.F. is a consultant to Genentech, Optovue, Zeiss, Heidelberg Engineering, Allergan,

and Novartis. C.A.C. receives research funds from Genentech/ Hoffman LaRoche and

Heidelberg Engineering and is a stockholder of MacRegen Inc.

Data and materials availability

All other data associated with this study are present in the paper or the Supplementary

Materials. Materials are available upon request from the corresponding author.

Figures and Captions

Figure 1. Hypothesis for complete retinal pigment epithelium (RPE) and outer

retinal atrophy (cRORA) in AMD[9] based on histology and OCT

This schematic for non-neovascular AMD is adapted from Zanzottera et al. [44] Six

morphologic phenotypes of RPE from a system of 15 [27] are shown. (**1**) Age-normal

"nonuniform" RPE overlies Bruch's membrane (BrM), which has abundant lipoprotein

particles (yellow). Basal laminar deposit (BLamD, green) is thickened basement

membrane material between the RPE cell body and native RPE basal lamina. RPE

organelles are melanosomes (black), lipofuscin (yellow), and mitochondria (pink). [6] (**2**)

Anteriorly migrated RPE ("sloughed" and "intraretinal") manifest clinically as HRF.

"Shedding" cells release organelle clusters [15] (arrow) basally into BLamD, thought to

represent apoptosis. (**3**) Due to cell death and migration, the RPE layer disintegrates.

"Dissociated" RPE are fully pigmented, nucleated cells scattered in the atrophic zone.

BLamD persists after RPE death. (**4)** "Subducted" cells containing RPE organelles,

appearing to originate from Dissociated cells (arrow), are flattened against BrM. (**5**)

"Subducted" cells migrate outside the atrophic area.

Figure 2. **Morphology of retinal pigment epithelium plumes.**

Examples from two eyes of one patient. (**A**) "Curvilinear" consists of hyperreflective

structures of consistent width, often arising from a soft druse and aiming towards the

outer plexiform layer. (**B**) "Thread" has a uniform and thin width, compared to

Curvilinear. (**C**) "Comma" has a wide base adjacent to the RPE layer and an anterior

taper. (**D**) "Vitelliform" is thick and arises from an acquired vitelliform lesion. [24]

Figure 3. **Retinal pigment epithelium plumes evolve over time.**

(**A** to **E**) Tracked optical coherence tomography B-scans of 5 different eyes with AMD

are shown with individualized colored frames and scale bars. Numbers in the lower right

corners indicate time elapsed in months since the baseline visit at 0 months. (**A1** to **A4**)

Hyperreflective foci (HRF) overlie a drusenoid pigment epithelial detachment that

collapsed at 12 months. HRF evolve into a comma plume before disappearing into

complete outer retinal atrophy (cORA [9]). (**B1** to **B6**) A curvilinear plume evolves into a

vitelliform plume, which collapses, leaving atrophy and degenerative cysts. (**C1** to **C3)** A

comma-type plume evolves into HRF upon drusen collapse. (**D1** to **D3**) Of two thread

plumes at baseline, one (left) becomes curvilinear at 3 months and persists through

drusen collapse and *incomplete* RPE and outer retinal atrophy at 13 months. Thread

plume at the right has disappeared at 13 months. (**E1** to **E2**) Two thread plumes evolve

into a comma plume as an RPE elevation appears. This eye also has an epiretinal

membrane.

Figure 4. HRF in *ex vivo* OCT match intraretinal RPE on histology.

Reflective features including hyperreflective foci (HRF) are visible in donor eyes (eye

numbers in Supplementary Table 7) by *ex vivo* optical coherence tomography (A1 to

F1). These were matched with RPE phenotypes in histology sections stained with

periodic acid Schiff hematoxylin (PASH) (A2 to F2), to show Bruch's membrane (BrM),

basal laminar deposit, and drusen. In all panels, scale bars are 200 μm; yellow

arrowheads indicate BrM, and green arrowheads indicate HRF in OCT and ectopic RPE

in histology. (**A1** and **A2)** HRFs above soft drusen at fovea from early-intermediate AMD

eye (#5). (**B1** and **B2)** HRFs at the fovea and nasal and temporal side, from atrophic

AMD eye (#17). (**C1** and **C2)** RPE plume in atrophic AMD eye (#15). (**D1** and **D2)**

Hyperreflective dots in OCT and dissociated RPE atop thick BLamD in the atrophic area.

(**E1** and **E2**) Reflective dots under an island of surviving photoreceptors in the fovea

582   center of an atrophic AMD eye (#12). (**F1** and **F2**) Multiple HRFs nasal to the fovea in an

583   early-intermediate AMD eye (#7), corresponding to intraretinal RPE cells.

Figure 5. RPE corresponding to HRF and other abnormal cells are CD68+.

Twenty donor eyes (16 AMD, 4 controls; eye numbers in Supplementary Table 7) were

used for immunohistochemistry with mouse monoclonal anti-human CD68

(Supplementary Table 1) and red reaction product. Fourteen of 16 previously described

morphologic phenotypes of RPE [27] were identified (Supplementary Table 2). All scale

bars are 20 µm; yellow arrowheads indicate BrM, and green arrowheads indicate

abnormal RPE phenotypes. (**A**) CD68- "Uniform" RPE, unremarkable (#1). (**B**) CD68-

granule aggregates, released basally from "Shedding" RPE; atrophic AMD (#13). (**C**)

CD68+ "Sloughed" RPE; atrophic AMD (#12). **D.** Both CD68+ and CD68- "Entombed"

RPE; nvAMD (#18). (**C**) A single CD68+ "Nonuniform" RPE from a less-affected area,

nvAMD (#20). (**F**) CD68+ "Intraretinal" RPE; early-intermediate AMD (#7). (**G**) Variable

CD68 immunoreactivity in "Melanotic" RPE, nvAMD (#18). CD68 immunoreactivity is

variable on heavily and light pigmented melanotic RPE. **H.** CD68+ "Severe" RPE;

atrophic AMD (#13). (**I**) CD68+ "Subducted" RPE, atrophic AMD (#12). (**J**) CD68+

"Entubulated" RPE, atrophic AMD (#12). (**K**) CD68+ "Dissociated" RPE, atrophic AMD

601   (#12). (**L**) CD68+ "Dissociated" RPE and "Sloughed" RPE, early-intermediate AMD (#7).

602   (**M**) Variable CD68 immunoreactivity in ''Bilaminar'' RPE, nvAMD (#20). (**N**) CD68+

603   "Dissociated" RPE; atrophic AMD (#12).

Figure 6. RPE corresponding to HRF and other abnormal cells are CD163+.

Twenty donor eyes (16 AMD, 4 controls; eye number in Supplementary Table 7) were

used for immunohistochemistry with mouse monoclonal anti-human CD163

(Supplementary Table 1) and red reaction product. Fourteen of 16 previously described

morphologic phenotypes of RPE were identified (Supplementary Table 2). All scale bars

are 20 µm; yellow arrowheads indicate BrM, and green arrowheads indicate abnormal

RPE phenotypes. (**A**) CD163- "Uniform" RPE, unremarkable (#1). (**B**) CD163-

"Shedding" RPE, nvAMD (#20). (**C**) CD163+ "Sloughed", nvAMD (#20). (**D**) Both

CD163+ and CD163- are present in "Entombed" RPE, nvAMD (#20). (**E**) A single

CD163+migrating RPE above "Nonuniform" RPE layer, atrophic AMD (#17). (**F**) CD163+

"Intraretinal" RPE, atrophic AMD (#15). (**G**) Variable CD163 immunoreactivities in

"Melanotic" RPE, nvAMD (#20). (**H**) CD163+ "Severe" or "Very nonuniform" RPE,

nvAMD (#20). (**I**) CD163+ "Subducted" and "Sloughed" RPE, atrophic AMD (#16). (**J**)

CD163+ "Entubulated" and "Dissociated" RPE, nvAMD (#20). (**K**) There is no RPE in an

area of "Atrophy without BLamD", atrophic AMD (#16). (**L**) CD163+ "Dissociated" and

621   "Intraretinal" RPE, atrophic AMD (#16). (**M**) Variable CD163 immunoreactivity in

622   ''Bilaminar'' RPE, nAMD (#20). (**N**) CD163+ "Intraretinal" RPE at ''Atrophy with BLamD''

623   area, atrophic AMD (#14).

Figure 7. RPE corresponding to HRF are RPE65-, as are other abnormal cells.

Twenty donor eyes (16 AMD, 4 controls; eye numbers in Supplementary Table 7) were

used for immunohistochemistry with mouse monoclonal anti-human RPE65

(Supplementary Table 1) and red reaction product. Fourteen of 16 previously described

morphologic phenotypes of RPE [27] were identified (Supplementary Table 2). All scale

bars are 20 µm; yellow arrowheads indicate BrM; green and fuchsia arrowheads indicate

RPE65- and RPE65+ abnormal RPE phenotypes, respectively. (**A**) RPE65+ "Uniform"

RPE, unremarkable (#1). (**B**) RPE65- "Shedding" RPE, nvAMD (#20). (**C**) RPE65-

"Sloughed" RPE, atrophic AMD (#13). (**D**) Both RPE65+ and REP65- "Entombed" RPE,

nvAMD (#18). (**E**) A few RPE65- "Nonuniform" RPE, early-intermediate AMD (#6). (**F**)

RPE65- "Intraretinal" RPE, early-intermediate AMD (#11). (**G**) Variable RPE65

immunoreactive "Melanotic" RPE, nvAMD (#18). (**H**) RPE65- "Severe" RPE, atrophic

AMD (#12). (**I**) RPE65- "Subducted" RPE, atrophic AMD (#12). (**J**) Both RPE65+ and

RPE65- "Entubulated" RPE, atrophic AMD (#12). (**K**) RPE65- RPE at "Atrophy without

BLamD" area, atrophic AMD (#12). (**L**) RPE65- "Dissociated" RPE, atrophic AMD (#16).

642   (**M**) Both RPE65- and RPE65+ ''Bilaminar'' RPE, nvAMD (#20). (**N**) RPE65- RPE at

643   ''Atrophy with BLamD'' area, atrophic AMD (#13).

Figure 8. Abnormal RPE is CRALBP-, Müller glia are CRALBP+.

Twenty donor eyes (16 AMD, 4 controls; eye numbers in Supplementary Table 7) were

used for immunohistochemistry with mouse monoclonal anti-human CRALBP

(Supplementary Table 1) and red reaction product. Fourteen of 16 previously described

morphologic phenotypes of RPE [27] were identified (Supplementary Table 2). All scale

bars are 20 μm. Yellow arrowheads indicate BrM. Green and fuchsia arrowheads

indicate CRALBP- and CRALBP+ abnormal RPE phenotypes, respectively. In panel L,

labeled Müller glia are seen at the external limiting membrane (ELM), pericellular

baskets in ONL (orange arrowhead), and parallel fibers in HFL. (**A**) CRALBP+ "Uniform"

RPE, unremarkable (#1). (**B**) CRALBP- "Shedding" RPE, early-intermediate AMD (#6).

(**C**) CRALBP- "Sloughed" RPE, atrophic AMD (#13). (**D**) Both CRALBP+ and CRALBP-

"Entombed" RPE nvAMD (#18). (**E**) CRALBP- "Nonuniform" RPE nvAMD (#18). (**F**)

CRALBP- "Intraretinal" RPE, early-intermediate AMD eye (#7). (**G**) Both CRALBP+ and

CRALBP- "Melanotic" RPE, nvAMD (#18). (**H**) CRALBP- "Severe" RPE, atrophic AMD

(#12). (**I**) CRALBP- "Subducted" RPE, atrophic AMD (#12). (**J**) Both CRALBP+ and

CRALBP- ''Entubulated'' RPE, atrophic AMD (#12). (**K**) CRALBP- RPE at ''Atrophy

without BLamD'' area, atrophic AMD (#12). (**L**) CRALBP- "Dissociated" RPE, early-

intermediate AMD (#7). (**M**) Variable CRALBP immunoreactivity in ''Bilaminar'' RPE,

nvAMD (#20). (**N**) Variable CRALBP+ and CRALBP- RPE at ''Atrophy with BLamD''

area, nvAMD (#7).

Figure 9. RPE migrate toward vessels and follow Müller glial columns.

One eye from each of two donors aged 86-90 years (#5 and #15, Supplementary Table

7) were subjected to *ex vivo* OCT images in A (Fig. 4, C1 and C2) and PASH staining

with cryosections in B, E and F. (**A**) *Ex vivo* OCT of donor eye (#5) shows HRF (yellow

arrowhead) over a large druse. (**B**) Corresponding PASH histologic section 290 µm

superior to the fovea with a big druse (d), artifactually detached (x) from the RPE, and

thinner ONL. (**C**) Magnified RPE rosette in B (yellow arrowheads) crossing the HFL and

approaching retinal capillaries (green arrowheads). (**D**) Nucleated RPE rosette from

panel C (adjacent section). RPE-characteristic spindle-shaped melanosomes and

melanolipofuscin impart a brown hue. The surrounded capillary is stained light pink

(green arrowhead) with endothelial cell nuclei. Processes containing RPE organelles

extend along the capillaries. (**E** and **F**) In another plume, RPE cells and detritus take a Z-

shaped course. Fully pigmented RPE cells cross the obliquely oriented fibers of the HFL,

with individual and grouped organelles in the lead (thin yellow arrows). The path turns

vertically to enter and cross the INL and IPL.

References

References

1.   Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and
distance vision impairment 1990-2020: a systematic review and meta-analysis. *The*
Lancet Global Health 2017;5:e1221-e1234. PMID 29032195
2.   Maguire MG, Martin DF, Ying GS, et al. Five-year outcomes with anti-vascular
endothelial growth factor treatment of neovascular age-related macular degeneration:
the Comparison of Age-Related Macular Degeneration Treatments Trials.
Ophthalmology 2016;123:1751-1761. PMID 27156698
3.   Chen L, Messinger JD, Kar D, Duncan JL, Curcio CA. Biometrics, impact, and
significance of basal linear deposit and subretinal drusenoid deposit in age-related
macular degeneration. *Invest Ophthalmol Vis Sci* 2021;62:33. PMID 33512402
4.   Keane PA, Patel PJ, Liakopoulos S, Heussen FM, Sadda SR, Tufail A. Evaluation
of age-related macular degeneration with optical coherence tomography. *Surv*
Ophthalmol 2012;57:389-414. PMID 22898648
5.   Guymer RH, Rosenfeld PJ, Curcio CA, et al. Incomplete retinal pigment epithelial
and outer retinal atrophy (iRORA) in age-related macular degeneration: CAM Report 4.
Ophthalmology 2020;127:394-409. PMID 31708275
6.   Pollreisz A, Neschi M, Sloan KR, et al. An atlas of human retinal pigment
epithelium organelles significant for clinical imaging. *Invest Ophthalmol Vis Sci*
2020;61:13. PMID 32648890
7.   Li M, Huisingh C, Messinger JD, et al. Histology of geographic atrophy secondary
to age-related macular degeneration: a multilayer approach. *Retina* 2018;38:1937-1953.
PMID 29746415
8.   Holz FG, Sadda S, Staurenghi G, et al. Imaging protocols for clinical studies in
age-related macular degeneration – recommendations from Classification of Atrophy
(CAM) Consensus Meeting. *Ophthalmology* 2017;124:464-478. PMID 28109563
9.   Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated
with age-related macular degeneration on optical coherence tomography: CAM Report
3. *Ophthalmology* 2018;125:537-548. PMID 29103793
10.   Jaffe GJ, Chakravarthy U, Freund KB, et al. Imaging features associated with
progression to geographic atrophy in age-related macular degeneration: CAM Report 5.
Ophthalmology Retina 2020;12/20/20 online. PMID 33348085
11.   Ouyang Y, Heussen FM, Hariri A, Keane PA, Sadda SR. Optical coherence
tomography-based observation of the natural history of drusenoid lesion in eyes with dry
age-related macular degeneration. *Ophthalmology* 2013;120:2656-2665. PMID
23830761
12.   Christenbury JG, Folgar FA, O'Connell RV, Chiu SJ, Farsiu S, Toth CA.
Progression of intermediate age-related macular degeneration with proliferation and
inner retinal migration of hyperreflective foci. *Ophthalmology* 2013;120:1038-1045. PMID
23352193
13.   Nassisi M, Lei J, Abdelfattah NS, et al. OCT risk factors for development of late
age-related macular degeneration in the fellow eyes of patients enrolled in the HARBOR
study. *Ophthalmology* 2019;126:1667-1674. PMID 31281056
14.   Waldstein SM, Vogl W-D, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth
U. Characterization of drusen and hyperreflective foci as biomarkers for disease
progression in age-related macular degeneration using artificial intelligence in optical
coherence tomography. *JAMA Ophthalmology* 2020;138:740-747. PMID 32379287

15.   Zanzottera EC, Messinger JD, Ach T, Smith RT, Freund KB, Curcio CA. The
Project MACULA retinal pigment epithelium grading system for histology and optical
coherence tomography in age-related macular degeneration. *Invest Ophthalmol Vis Sci*
2015;56:3253-3268. PMID 25813989
16.   Zanzottera EC, Messinger JD, Ach T, Smith RT, Curcio CA. Subducted and
Melanotic cells in advanced age-related macular degeneration are derived from retinal
pigment epithelium. *Invest Ophthalmol Vis Sci* 2015;56:3269-3278. PMID 26024109
17.   Balaratnasingam C, Messinger JD, Sloan KR, Yannuzzi LA, Freund KB, Curcio
CA. Histologic and optical coherence tomographic correlations in drusenoid pigment
epithelium detachment in age-related macular degeneration. *Ophthalmology*
2017;124:644-656. PMID 28153442
18.   Li M, Dolz-Marco R, Messinger JD, et al. Clinicopathologic correlation of anti-
vascular endothelial growth factor-treated type 3 neovascularization in age-related
macular degeneration. *Ophthalmology* 2018;125:276-287. PMID 28964579
19.   Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and
reprogramming: three routes to regeneration. *Nat Rev Mol Cell Biol* 2011;12:79-89.
PMID 21252997
20.   Pang C, Messinger JD, Zanzottera EC, Freund KB, Curcio CA. The Onion Sign in
neovascular age-related macular degeneration represents cholesterol crystals.
Ophthalmology 2015;122:2316-2326. PMID 26298717
21.   Ghosh S, Shang P, Terasaki H, et al. A role for betaA3/A1-crystallin in Type 2 EMT
of RPE cells occurring in dry age-related macular degeneration. *Invest Ophthalmol Vis*
Sci 2018;59:AMD104-AMD113. PMID 30098172
22.   Staurenghi G, Sadda S, Chakravarthy U, Spaide RF. Proposed lexicon for
anatomic landmarks in normal posterior segment spectral-domain optical coherence
tomography: The IN*OCT Consensus. *Ophthalmology* 2014;121:1572-1578. PMID
24755005
23.   Sura AA, Chen L, Messinger JD, et al. Measuring the contributions of basal laminar
deposit and Bruch's membrane in age-related macular degeneration. *Invest Ophthalmol*
Vis Sci 2020;61:19. PMID 33186466
24.   Freund KB, Laud K, Lima LH, Spaide RF, Zweifel S, Yannuzzi LA. Acquired
vitelliform lesions: correlation of clinical findings and multiple imaging analyses. *Retina*
2011;31:13-25. PMID 21102371
25.   Tan ACS, Freund KB, Balaratnasingam C, Simhaee D, Yannuzzi LA. Imaging of
pigment epithelial detachments with optical coherence tomography angiography. *Retina*
2018;38:1759-1769. PMID 29293207
26.   Jakobiec FA, Barrantes PC, Yonekawa Y, Lad EM, Proia AD. Subretinal
mononuclear cells in Coats' disease studied with RPE65 and CD163: evidence for
histiocytoid pigment epithelial cells. *American Journal of Ophthalmology* 2020;222:388-
396. PMID 32950512
27.   Curcio CA, Zanzottera EC, Ach T, Balaratnasingam C, Freund KB. Activated retinal
pigment epithelium, an optical coherence tomography biomarker for progression in age-
related macular degeneration. *Invest Ophthalmol Vis Sci* 2017;58:BIO211-BIO226.
PMID 28785769
28.   Sparrow JR, Marsiglia M, Allikmets R, et al. Flecks in recessive Stargardt disease:
short-wavelength autofluorescence, near-infrared autofluorescence, and optical
coherence tomography. *Invest Ophthalmol Vis Sci* 2015;56:5029-5039. PMID 26230768

29.   Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage
polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages.
PLoS One 2013;8:e80908. PMID 24260507
30.   Chistiakov DA, Killingsworth MC, Myasoedova VA, Orekhov AN, Bobryshev YV.
CD68/macrosialin: not just a histochemical marker. *Lab Invest* 2017;97:4-13. PMID
27869795
31.   Schaal KB, Freund KB, Litts KM, Zhang Y, Messinger JD, Curcio CA. Outer retinal
tubulation in advanced age-related macular degeneration: optical coherence
tomographic findings correspond to histology. *Retina* 2015;35:1339-1350. PMID
25635579
32.   Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and
therapeutic aspects. *Antioxid Redox Signal* 2013;18:2352-2363. PMID 22900885
33.   Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal
microglia: just bystander or target for therapy? *Prog Retin Eye Res* 2015;45:30-57. PMID
25476242
34.   Lad EM, Cousins SW, Proia AD. Identity of pigmented subretinal cells in age-
related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2016;254:1239-1241.
PMID 26728757
35.   Margeta MA, Lad EM, Proia AD. CD163+ macrophages infiltrate axon bundles of
postmortem optic nerves with glaucoma. *Graefes Arch Clin Exp Ophthalmol*
2018;256:2449-2456. PMID 30073622
36.   Lamb TD, Pugh EN, Jr. Phototransduction, dark adaptation, and rhodopsin
regeneration: the Proctor Lecture. *Invest Ophthalmol Vis Sci* 2006;47:5137-5152. PMID
17122096
37.   Saari JC. Vitamin A and Vision. *Subcell Biochem* 2016;81:231-259. PMID
27830507
38.   von Lintig J, Moon J, Babino D. Molecular components affecting ocular carotenoid
and retinoid homeostasis. *Prog Retin Eye Res* 2021;80:100864. PMID 32339666
39.   Xue Y, Shen SQ, Jui J, et al. CRALBP supports the mammalian retinal visual cycle
and cone vision. *J Clin Invest* 2015;125:727-738. PMID 25607845
40.   Liu T, Jenwitheesuk E, Teller DC, Samudrala R. Structural insights into the cellular
retinaldehyde-binding protein (CRALBP). *Proteins* 2005;61:412-422. PMID 16121400
41.   Ach T, Tolstik E, Messinger JD, Zarubina AV, Heintzmann R, Curcio CA.
Lipofuscin re-distribution and loss accompanied by cytoskeletal stress in retinal pigment
epithelium of eyes with age-related macular degeneration. *Invest Ophthalmol Vis Sci*
2015;56:3242-3252. PMID 25758814
42.   Omri S, Omri B, Savoldelli M, et al. The outer limiting membrane (OLM) revisited:
clinical implications. *Clin Ophthalmol* 2010;4:183-195. PMID 20463783
43.   Polyak SL. *The Retina*. Chicago: University of Chicago; 1941.
44.   Zanzottera EC, Ach T, Huisingh C, Messinger JD, Spaide RF, Curcio CA.
Visualizing retinal pigment epithelium phenotypes in the transition to geographic atrophy
in age-related macular degeneration. *Retina* 2016;36 Suppl 1:S12-S25. PMID 27658287
45.   Matet A, Savastano MC, Rispoli M, et al. En face optical coherence tomography of
foveal microstructure in full-thickness macular hole: a model to study perifoveal Muller
cells. *Am J Ophthalmol* 2015;159:1142-1151 e1143. PMID 25728860
46.   Lei J, Balasubramanian S, Abdelfattah NS, Nittala M, Sadda SR. Proposal of a
simple optical coherence tomography-based scoring system for progression of age

related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2017;255:1551-1558.
PMID 28534244
47. Nicolai U, Eckardt C. The occurrence of macrophages in the retina and periretinal
tissues in ocular diseases. *Ger J Ophthalmol* 1993;2:195-201. PMID 8220098
48. Sheridan C, Hiscott P, Grierson I. Retinal pigment epithelium differentiation and
dedifferentiation. In: Kirchhof B, Wong D (eds), *Vitreo-retinal Surgery Essentials in*
Ophthalmology Berlin, Heidelberg: Springer; 2005.
49. Bonilha VL, Bell BA, Hu J, et al. Geographic atrophy: confocal scanning laser
ophthalmoscopy, histology, and inflammation in the region of expanding lesions. *Invest*
Ophthalmol Vis Sci 2020;61:15. PMID 32658960
50. Matsubara JA, Tian Y, Cui JZ, et al. Retinal distribution and extracellular activity of
granzyme B: a serine protease that degrades retinal pigment epithelial tight junctions
and extracellular matrix proteins. *Front Immunol* 2020;11:574. PMID 32318066
51. Chen KC, Jung JJ, Curcio CA, et al. Intraretinal hyperreflective foci in acquired
vitelliform lesions of the macula: clinical and histologic study. *Am J Ophthalmol*
2016;164:89-98. PMID 26868959
52. Cherepanoff S, McMenamin PG, Gillies MC, Kettle E, Sarks SH. Bruch's
membrane and choroidal macrophages in early and advanced age-related macular
degeneration. *Br J Ophthalmol* 2010;94:918-925. PMID 19965817
53. McLeod DS, Bhutto I, Edwards MM, Silver RE, Seddon JM, Lutty GA. Distribution
and quantification of choroidal macrophages in human eyes with age-related macular
degeneration. *Invest Ophthalmol Vis Sci* 2016;57:5843-5855. PMID 27802514
54. Elner SG, Elner VM, Nielsen JC, Torczynski E, Yu R, Franklin WA. CD68 antigen
expression by human retinal pigment epithelial cells. *Exp Eye Res* 1992;55:21-28. PMID
1397126
55. Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and
proliferation in human choroidal neovascularization. *Arch Ophthalmol* 2008;126:782-790.
PMID 18541840
56. Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, Kent D. Expression of
hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular
membranes. *Graefes Arch Clin Exp Ophthalmol* 2009;247:1361-1367. PMID 19590888
57. Ghazi-Nouri SM, Assi A, Limb GA, et al. Laser photocoagulation alters the pattern
of staining for neurotrophin-4, GFAP, and CD68 in human retina. *Br J Ophthalmol*
2003;87:488-492. PMID 12642316
58. Simsek M, Ozates S, Gulpamuk B, Buyukeren B, Teke MY. Dedifferentiation of
retinal pigment epithelium in a patient with chronic retinal detachment. *Ophthalmic Surg*
Lasers Imaging Retina 2018;49:716-720. PMID 30222808
59. Josifovska N, Lumi X, Szatmari-Toth M, et al. Clinical and molecular markers in
retinal detachment-From hyperreflective points to stem cells and inflammation. *PLoS*
One 2019;14:e0217548. PMID 31185026
60. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the
retinal pigment epithelium. *Eye* 1988;2:552-577. PMID 2476333
61. Gocho K, Sarda V, Falah S, et al. Adaptive optics imaging of geographic atrophy.
Invest Ophthalmol Vis Sci 2013;54:3673-3680. PMID 23620431
62. Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the
involvement of immunocompetent cells. *Graefes Arch Clin Exp Ophthalmol* 1985;223:69-
76. PMID 2408968

63.   Sennlaub F, Auvynet C, Calippe B, et al. CCR2(+) monocytes infiltrate atrophic
lesions in age-related macular disease and mediate photoreceptor degeneration in
experimental subretinal inflammation in Cx3cr1 deficient mice. *EMBO Mol Med*
2013;5:1775-1793. PMID 24142887
64.   Schlereth SL, Kremers S, Schrodl F, Cursiefen C, Heindl LM. Characterization of
antigen-presenting macrophages and dendritic cells in the healthy human sclera. *Invest*
Ophthalmol Vis Sci 2016;57:4878-4885. PMID 27654414
65.   Shirazi MF, Brunner E, Laslandes M, Pollreisz A, Hitzenberger CK, Pircher M.
Visualizing human photoreceptor and retinal pigment epithelium cell mosaics in a single
volume scan over an extended field of view with adaptive optics optical coherence
tomography. *Biomed Opt Express* 2020;11:4520-4535. PMID 32923061
66.   Lee B, Chen S, Moult EM, et al. High-speed, ultrahigh-resolution spectral-domain
OCT with extended imaging range using reference arm length matching. *Translational*
Vision Science & Technology 2020;9:12-12. PMID 32832219
67.   Wu Z, Luu CD, Hodgson LAB, et al. Prospective longitudinal evaluation of nascent
geographic atrophy in age-related macular degeneration. *Ophthalmol Retina* 2019.
PMID 32088159
68.   Dolz-Marco R, Litts KM, Tan ACS, Freund KB, Curcio CA. The evolution of outer
retinal tubulation, a neurodegeneration and gliosis prominent in macular diseases.
Ophthalmology 2017;124:1353-1367. PMID 28456420
69.   Edwards MM, McLeod DS, Bhutto IA, Grebe R, Duffy M, Lutty GA. Subretinal glial
membranes in eyes with geographic atrophy. *Invest Ophthalmol Vis Sci* 2017;58:1352-
1367. PMID 28249091
70.   Chen L, Messinger JD, Ferrara D, Freund KB, Curcio CA. Stages of drusen-
associated atrophy in age-related macular degeneration visible via histologically
validated fundus autofluorescence. *Ophthalmology Retina* 2020;11/30/20 online. PMID
33217617
71.   Tan AC, Pilgrim M, Fearn S, et al. Calcified nodules in retinal drusen are
associated with disease progression with age-related macular degeneration. *Sci Transl*
Med 2018;10:466-477. PMID 30404862
72.   Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-
mesenchymal transition. *Nat Rev Mol Cell Biol* 2020;21:341-352. PMID 32300252
73.   Gilmore AP. Anoikis. *Cell Death Differ* 2005;12 Suppl 2:1473-1477. PMID
16247493
74.   Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer
progression. *Biochim Biophys Acta* 2013;1833:3481-3498. PMID 23830918
75.   Zhou M, Geathers JS, Grillo SL, et al. Role of epithelial-mesenchymal transition in
retinal pigment epithelium dysfunction. *Front Cell Dev Biol* 2020;8:501. PMID 32671066
76.   Guidry C, Medeiros NE, Curcio CA. Phenotypic variation of retinal pigment
epithelium in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2002;43:267-
273. PMID 11773041
77.   Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early
age-related maculopathy. *Archives of Ophthalmology* 1999;117:329-339. PMID
10088810
78.   Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PGH, de Jong
PTVM. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the
choroid in aging. *Invest Ophthalmol Vis Sci* 1994;35:2857-2864. PMID 8188481

79.   Mullins RF, Johnson MN, Faidley EA, Skeie JM, Huang J. Choriocapillaris vascular
dropout related to density of drusen in human eyes with early age-related macular
degeneration. *Investigative Ophthalmology & Visual Science* 2011;52:1606-1612. PMID
21398287
80.   Seddon JM, McLeod DS, Bhutto IA, et al. Histopathological insights into choroidal
vascular loss in clinically documented cases of age-related macular degeneration. *JAMA*
Ophthalmol 2016;134:1272-1280. PMID 27657855
81.   Lutty GA, McLeod DS, Bhutto IA, Edwards MM, Seddon JM. Choriocapillaris
dropout in early age-related macular degeneration. *Exp Eye Res* 2020;107939. PMID
31987759
82.   Balaratnasingam C, Yannuzzi LA, Curcio CA, et al. Associations between retinal
pigment epithelium and drusen volume changes during the lifecycle of large drusenoid
pigment epithelial detachments. *Invest Ophthalmol Vis Sci* 2016;57:5479-5489. PMID
27760262
83.   Pan WW, Wubben TJ, Besirli CG. Photoreceptor metabolic reprogramming: current
understanding and therapeutic implications. *Commun Biol* 2021;4:245. PMID 33627778
84.   Hurley JB, Lindsay KJ, Du J. Glucose, lactate, and shuttling of metabolites in
vertebrate retinas. *J Neurosci Res* 2015;93:1079-1092. PMID 25801286
85.   Chinchore Y, Begaj T, Wu D, Drokhlyansky E, Cepko CL. Glycolytic reliance
promotes anabolism in photoreceptors. *Elife* 2017;6. PMID 28598329
86.   Lujan B, Roorda A, Knighton RW, Carroll J. Revealing Henle's fiber layer using
spectral domain optical coherence tomography. *Invest Ophthalmol Vis Sci*
2011;52:1486–1492. PMID 21071737
944